SPOTLIGHT: M&A is the future for Big Pharma

What's Big Pharma's best hope for weathering the next few years of expiring patents and patchy pipelines? M&A, says London's Financial Times. That's not exactly revolutionary, of course; there were almost 1,000 deals in pharma/healthcare for the first half of 2007, according to Pricewaterhouse Coopers. But FT fingers a few potential acquisition targets, including U.S.-based Sepracor and the U.K.'s Shire Pharmaceuticals. Article [1]